Hepatoprotection
|
WikiDoc Resources for Hepatoprotection |
|
Articles |
|---|
|
Most recent articles on Hepatoprotection Most cited articles on Hepatoprotection |
|
Media |
|
Powerpoint slides on Hepatoprotection |
|
Evidence Based Medicine |
|
Clinical Trials |
|
Ongoing Trials on Hepatoprotection at Clinical Trials.gov Trial results on Hepatoprotection Clinical Trials on Hepatoprotection at Google
|
|
Guidelines / Policies / Govt |
|
US National Guidelines Clearinghouse on Hepatoprotection NICE Guidance on Hepatoprotection
|
|
Books |
|
News |
|
Commentary |
|
Definitions |
|
Patient Resources / Community |
|
Patient resources on Hepatoprotection Discussion groups on Hepatoprotection Patient Handouts on Hepatoprotection Directions to Hospitals Treating Hepatoprotection Risk calculators and risk factors for Hepatoprotection
|
|
Healthcare Provider Resources |
|
Causes & Risk Factors for Hepatoprotection |
|
Continuing Medical Education (CME) |
|
International |
|
|
|
Business |
|
Experimental / Informatics |
Hepatoprotection or antihepatotoxicity is the ability to prevent damage to the liver.
An example of a hepatoprotective medicine is silibinin, derived from Milk Thistle, which selectively inhibits leukotriene formation by Kupffer cells.[1]
See also
References
- ↑ Inhibition of Kupffer cell functions as an explanation for the hepatoprotective properties of silibinin. Dehmlow, Carola; Erhard, Jochen; De Groot, Herbert. Hepatology (1996), 23(4), 749-54.